Crohn’s Disease | Unmet Need | US/EU | 2023
TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’s Entyvio, a CAM inhibitor, Janssen’s Stelara, an IL-12/23 inhibitor, and AbbVie’s Skyrizi, an IL-23 inhibitor) are mostly used as later-line therapies, following anti-TNF failure. These agents have safety risks and efficacy limitations, and the launch of biosimilar alternatives has only increased the complexity of CD treatment. Meanwhile, significant need remains, especially in the treatment of patients with CD refractory to available therapies and those with fistulizing disease.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for moderate to severe CD?
- Which drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for moderate to severe CD?
- What are the prevailing areas of unmet need and opportunity in moderate to severe CD?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European gastroenterologists for a hypothetical new moderate to severe CD drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 U.S. and 32 European gastroenterologists fielded in January 2023
Key companies: AbbVie, Janssen, Takeda, UCB, Celltrion Healthcare
Key drugs: Remicade, infliximab biosimilar (IV), Entyvio, Stelara, Skyrizi, Humira, adalimumab biosimilar, Remsima SC
